Protocols

AstraZeneca bags a ‘breakthrough’ for bruised checkpoint drug Imfinzi; Inotek CSO takes the helm at Flex

→ Just days after a damaging failure for duvalumab (Imfinzi) in a combination approach to lung cancer, the FDA has designated AstraZeneca’s checkpoint inhibitor as a “breakthrough” product deserving special treatment at the agency. Specifically, the BTD is for locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.

→  Italy’s Chiesi Group is handing back its European rights to uniQure’s hemophilia B gene therapy. Chiesi CEO Ugo Di Francesco says that the decision was driven by a change in “strategic priorities.”  UniQure CEO says the move leaves uniQure with unencumbered global rights to the therapy, which has demonstrated mixed results in the clinic.

→ Flex Pharma’s Christoph Westphal has selected Inotek CSO William McVicar as his replacement for the CEO job. The move comes after back-to-back failures at Inotek which decimated its stock.

→ Aerie Pharmaceuticals $AERI has struck a deal to collaborate with DSM, taking an option on some of their delivery tech for eye drugs.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Immuno Oncology 360

Bio NJ Annual Dinner